Revista: | Revista de investigación clínica |
Base de datos: | PERIÓDICA |
Número de sistema: | 000389659 |
ISSN: | 0034-8376 |
Autores: | Amador Medina, Lauro Fabián1 Lacayo Leñero, Dennis2 Crespo Solís, Erick2 Aguayo, Alvaro2 Martínez Baños, Déborah2 |
Instituciones: | 1Instituto Mexicano del Seguro Social, Hospital Regional de Alta Especialidad, León, Guanajuato. México 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Hematología y Oncología, Tlalpan, Distrito Federal. México |
Año: | 2015 |
Periodo: | Sep-Oct |
Volumen: | 67 |
Número: | 5 |
Paginación: | 304-312 |
País: | México |
Idioma: | Inglés |
Tipo de documento: | Estadística o encuesta |
Enfoque: | Caso clínico, analítico |
Resumen en inglés | Novel therapies for multiple myeloma are not affordable for all healthcare systems. Objectives: The objectives of this study were to evaluate the response rates, overall survival, event-free survival, and toxicity of thalidomide and dexamethasone administered until best response in recently diagnosed patients with multiple myeloma. Methods: All recently diagnosed multiple myeloma patients meeting the inclusion criteria received the same treatment with thalidomide and dexamethasone. Results: We studied 28 patients. Overall response rate was 75%. Complete response, partial response, and very good partial response were 25.0, 32.1, and 17.9%, respectively. The most frequent adverse event related to therapy was neuropathy. Median overall survival was 66 months, and median event-free survival was 39 months (range, 27.6-50.4). Variables that negatively affected overall survival on multivariate analysis included the presence of extramedullary disease, t(14;16), and chromosome 13 deletion. Conclusions: Induction therapy with thalidomide and dexamethasone until obtaining the best response in patients with recently diagnosed multiple myeloma was a useful and safe strategy. It represents an alternative for patients with limited access to costly drugs |
Disciplinas: | Medicina |
Palabras clave: | Oncología, Terapéutica y rehabilitación, Mieloma múltiple, Talidomida, Dexametasona, Eventos adversos, Sobrevivencia |
Keyword: | Medicine, Oncology, Therapeutics and rehabilitation, Multiple myeloma, Thalidomide, Dexamethasone, Adverse effects, Survival |
Texto completo: | Texto completo (Ver PDF) |